S Gütz

758 total citations
18 papers, 260 citations indexed

About

S Gütz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, S Gütz has authored 18 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in S Gütz's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (5 papers). S Gütz is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (5 papers). S Gütz collaborates with scholars based in Germany, Switzerland and Estonia. S Gütz's co-authors include Eckart Laack, Claus-Peter Schneider, Andreas G. Franke, Martin Reck, H. Bodenstein, David F. Heigener, W. Digel, Philipp A. Schnabel, Felix Herth and Michael Thomas and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Oncologist.

In The Last Decade

S Gütz

16 papers receiving 251 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Gütz Germany 7 197 173 51 47 32 18 260
Masayuki Shirasawa Japan 10 108 0.5× 167 1.0× 47 0.9× 27 0.6× 21 0.7× 25 213
Daniel Almquist United States 8 85 0.4× 169 1.0× 103 2.0× 59 1.3× 37 1.2× 18 303
Martin Kimmich Germany 9 239 1.2× 140 0.8× 21 0.4× 47 1.0× 12 0.4× 22 295
Elisabetta Gambale Italy 8 116 0.6× 178 1.0× 20 0.4× 47 1.0× 22 0.7× 19 246
Atsushi Sekimura Japan 11 108 0.5× 80 0.5× 20 0.4× 92 2.0× 44 1.4× 34 286
K. Lorizzo Italy 7 85 0.4× 155 0.9× 75 1.5× 33 0.7× 36 1.1× 20 227
Elena Simón Polo Spain 4 246 1.2× 225 1.3× 19 0.4× 31 0.7× 18 0.6× 8 310
Silvana Acquafredda Italy 6 94 0.5× 159 0.9× 20 0.4× 42 0.9× 40 1.3× 8 237
Haocan Song United States 7 74 0.4× 124 0.7× 23 0.5× 48 1.0× 28 0.9× 10 233
Naoki Omachi Japan 11 358 1.8× 268 1.5× 67 1.3× 70 1.5× 26 0.8× 26 432

Countries citing papers authored by S Gütz

Since Specialization
Citations

This map shows the geographic impact of S Gütz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Gütz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Gütz more than expected).

Fields of papers citing papers by S Gütz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Gütz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Gütz. The network helps show where S Gütz may publish in the future.

Co-authorship network of co-authors of S Gütz

This figure shows the co-authorship network connecting the top 25 collaborators of S Gütz. A scholar is included among the top collaborators of S Gütz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Gütz. S Gütz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Schmid‐Bindert, Gerald, Jens Vogel‐Claussen, S Gütz, et al.. (2022). Incidental Pulmonary Nodules – What Do We Know in 2022. Respiration. 101(11). 1024–1034. 31 indexed citations
3.
Frost, Nikolaj, Petros Christopoulos, Diego Kauffmann‐Guerrero, et al.. (2021). Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Therapeutic Advances in Medical Oncology. 13. 3863595598–3863595598. 33 indexed citations
4.
5.
Asselain, Bernard, Fabrice Barlési, D. Debieuvre, et al.. (2019). IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany. Annals of Oncology. 30. v614–v614. 2 indexed citations
6.
Christopoulos, Petros, Walburga Engel-Riedel, Christian Grohé, et al.. (2017). Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Annals of Oncology. 28(8). 1898–1902. 53 indexed citations
7.
Grohé, Christian, Walburga Engel-Riedel, Cornelia Kropf-Sanchen, et al.. (2017). P1.07-003 A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC. Journal of Thoracic Oncology. 12(1). S697–S697. 1 indexed citations
8.
9.
10.
Schüler, Martin, Jürgen R. Fischer, Christian Grohé, et al.. (2014). Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib. The Oncologist. 19(10). 1100–1109. 18 indexed citations
11.
Warth, Arne, Lukas Bubendorf, S Gütz, et al.. (2013). Molekularpathologische Diagnostik in der Zytopathologie des nichtkleinzelligen Lungenkarzinoms. Der Pathologe. 34(4). 310–317. 8 indexed citations
12.
Herth, Felix, Lukas Bubendorf, S Gütz, et al.. (2013). Diagnose und prädiktive Analysen an zytologischen und bioptischen Tumorproben nicht-kleinzelliger Lungenkarzinome: Aktuelle Strategien und Herausforderungen. Pneumologie. 67(4). 198–204. 13 indexed citations
13.
Gütz, S. (2009). Therapie des malignen Pleuramesothelioms. Der Pneumologe. 7(1). 36–42.
14.
Gütz, S. (2009). Mediastinaltumoren. Der Pneumologe. 6(3). 151–160. 1 indexed citations
15.
Schneider, Claus-Peter, David F. Heigener, S Gütz, et al.. (2008). Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study. Journal of Thoracic Oncology. 3(12). 1446–1453. 88 indexed citations
16.
Laack, Eckart, Andreas Krüll, Walburga Engel-Riedel, et al.. (2007). A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). Lung Cancer. 57(2). 181–186. 3 indexed citations
17.
Gütz, S, et al.. (2007). Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7674–7674. 5 indexed citations
18.
Gütz, S, et al.. (2004). Patient mit Pleuraerguss links und großen weichteildichten Strukturen im Mediastinum. Pneumologie. 58(10). 724–727. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Shirasawa Breakdown of academic impact, for papers by Daniel Almquist Breakdown of academic impact, for papers by Martin Kimmich Breakdown of academic impact, for papers by Elisabetta Gambale Breakdown of academic impact, for papers by Atsushi Sekimura Breakdown of academic impact, for papers by K. Lorizzo Breakdown of academic impact, for papers by Elena Simón Polo Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Haocan Song Breakdown of academic impact, for papers by Naoki Omachi
Rankless by CCL
2026